Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maraviroc advisory committee

Executive Summary

FDA's Antiviral Drugs Advisory Committee will meet April 24 to review Pfizer's potential first-in-class HIV therapy maraviroc, according to a notice in the Federal Register Feb. 7. Pfizer will market the CCR5 antagonist candidate with Monogram's co-receptor tropism assay Trofile to identify patients who are most likely to respond to the drug class (1"The Pink Sheet" Dec. 18, 2006, p. 11). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...

You may also be interested in...



Pfizer Maraviroc Assay In HIV Is Model For Personalized Medicine, Firm Says

Pfizer is putting forward its partnership with assay developer Monogram Biosciences to advance its CCR5 antagonist candidate maraviroc as a model for targeted drug development

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel